Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 21, 2021

Intersect ENT gets CE mark for PROPEL Contour sinus implant 

Intersect ENT obtains CE mark for its PROPEL Contour sinus implant, facilitating supply in the EU. 

Intersect ENT has obtained CE mark for PROPEL Contour (mometasone furoate) sinus implant, facilitating its marketing and supply in the EU.

The implant is designed to preserve patency, lessen inflammation and adapt to the sinus ostia or openings via mechanical support as well as the delivery of steroids in cases requiring enhanced sinus procedure outcomes.

A common medical condition, chronic rhinosinusitis affects people of all ages globally. Approximately 15% of chronic sinusitis patients in the UK undergo surgery upon failing therapies every year.

Excessive mucus drainage, nasal blockage, breathing problems, pain and tenderness around the eyes, cheeks, nose and forehead, a diminished smell and taste sense, and fatigue and irritability are some of the symptoms of chronic sinusitis.

Furthermore, these patients experience lower quality of life scores when compared to other common chronic diseases, such as congestive heart failure, angina, chronic obstructive pulmonary disease and back pain.

PROPEL Contour has an hourglass shape to enable positioning in the frontal sinuses between the eyebrows after sinus surgery in patients with chronic rhinosinusitis.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

The implant includes a low-profile flexible delivery system to facilitate easy access to the frontal sinus ostia areas.

The latest approval broadens the PROPEL product portfolio of drug-eluting, bioabsorbable implants, which currently includes PROPEL and PROPEL Mini available in the market.

Intersect ENT president and CEO Thomas West said: “Our goal is to offer sinus physicians the broadest range of products so they can customise treatment for each patient with focused drug delivery and mechanical support where it is needed to optimise sinus surgery outcomes.

“The introduction of Contour is consistent with our strategic growth initiatives, where we expect to see more significant revenue contributions from PROPEL and our other technology platforms across Europe over the coming years.”

The CE mark approval is based on positive data from the PROPEL Contour cohort of PROGRESS clinical study in the US.

This prospective, randomised, blinded, multi-centre trial evaluated the safety and efficacy of the implant placed in the frontal sinus ostia after endoscopic sinus surgery in 80 subjects.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU